This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Monocytosis Subsequent to Ziprasidone Treatment: A Possible Side Effect

Jan Thöne, MD, and Elke Kessler, MD

Published: December 14, 2007

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Ziprasidone is an atypical antipsychotic agent that is available as oral and short-acting intramuscular formulations and is approved by the U.S. Food and Drug Administration for management of schizophrenia and bipolar disorder. Ziprasidone acts as a serotonin and dopaminereceptor antagonist, with greater affinity for the 5-HT2Areceptor than the dopamine D2 receptor.1 Moreover, it possesses agonist activity at the serotonin 5-HT1A receptor.1


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 9

Quick Links: Bipolar Disorder

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...